H.R. 7248 · 118th Congress (2023–2025)
FDA Modernization Act 3.0
This bill requires the Food and Drug Administration (FDA) to establish a process that supports nonclinical testing methods for drug development that do not involve the use of animals.
Specifically, the FDA must establish a pathway by which entities may apply to have nonclinical testing methods approved for use in a particular context. Qualifying methods must be intended to replace or reduce animal testing and to either improve the safety and efficacy of nonclinical testing or reduce the time to develop a drug. The FDA must issue its decision within 180 days of receiving an application. The FDA must also prioritize the review of applications for drugs that are developed using an approved nonclinical testing method.
The FDA must annually post a report on its website that summarizes the results of the bill's implementation, including the number of applications received, types of methods that were approved, and the estimated number of animals saved as result of these methods.
Show official title
To amend the Federal Food, Drug, and Cosmetic Act to establish a process for the qualification of nonclinical testing methods to reduce and replace the use of animals in nonclinical research, improve the predictivity of nonclinical testing methods, and reduce development time for a biological product or other drug, and for other purposes.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 7248’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Earl L. "Buddy" Carter (R-GA-1)
- Cosponsors
46 cosponsors
10 original · 36 later
22 R · 24 D
- Rep. Vern Buchanan (R-FL-16)· Original · Feb 6, 2024
- Rep. Nanette Diaz Barragán (D-CA-44)· Original · Feb 6, 2024
- Rep. Dan Crenshaw (R-TX-2)· Original · Feb 6, 2024
- Rep. Troy A. Carter (D-LA-2)· Original · Feb 6, 2024
- Rep. Rosa L. DeLauro (D-CT-3)· Original · Feb 6, 2024
- Rep. Brian K. Fitzpatrick (R-PA-1)· Original · Feb 6, 2024
- Rep. Lance Gooden (R-TX-5)· Original · Feb 6, 2024
- Rep. Diana Harshbarger (R-TN-1)· Original · Feb 6, 2024
- Rep. Troy E. Nehls (R-TX-22)· Original · Feb 6, 2024
- Rep. Michael Waltz (R-FL-6)· Original · Feb 6, 2024
- Rep. David G. Valadao (R-CA-22)· Later · Feb 13, 2024
- Rep. Joe Neguse (D-CO-2)· Later · Feb 14, 2024
- Rep. Gus M. Bilirakis (R-FL-12)· Later · Feb 23, 2024
- Rep. Donald G. Davis (D-NC-1)· Later · Feb 23, 2024
- Rep. Josh Gottheimer (D-NJ-5)· Later · Feb 29, 2024
- Rep. Daniel S. Goldman (D-NY-10)· Later · Mar 5, 2024
- Del. Eleanor Holmes Norton (D-DC)· Later · Mar 5, 2024
- Rep. Deborah K. Ross (D-NC-2)· Later · Mar 11, 2024
- Rep. Brittany Pettersen (D-CO-7)· Later · Mar 19, 2024
- Rep. Zoe Lofgren (D-CA-18)· Later · Mar 21, 2024
- Rep. Dina Titus (D-NV-1)· Later · Mar 22, 2024
- Rep. Michael Lawler (R-NY-17)· Later · Mar 29, 2024
- Rep. Jay Obernolte (R-CA-23)· Later · Apr 5, 2024
- Rep. Rashida Tlaib (D-MI-12)· Later · Apr 17, 2024
- Rep. Tim Burchett (R-TN-2)· Later · Apr 19, 2024
- Rep. Christopher H. Smith (R-NJ-4)· Later · Apr 19, 2024
- Rep. Nancy Mace (R-SC-1)· Later · Apr 23, 2024
- Rep. Scott Fitzgerald (R-WI-5)· Later · May 1, 2024
- Rep. Don Bacon (R-NE-2)· Later · May 10, 2024
- Rep. Kevin Mullin (D-CA-15)· Later · May 14, 2024
- Rep. Tony Cárdenas (D-CA-29)· Later · May 21, 2024
- Rep. Mike Carey (R-OH-15)· Later · Jun 3, 2024
- Rep. Jesús G. "Chuy" García (D-IL-4)· Later · Jun 5, 2024
- Rep. Judy Chu (D-CA-28)· Later · Jul 22, 2024
- Rep. Lois Frankel (D-FL-22)· Later · Jul 22, 2024
- Rep. Hillary J. Scholten (D-MI-3)· Later · Aug 16, 2024
- Rep. Jason Crow (D-CO-6)· Later · Aug 23, 2024
- Rep. Anthony D'Esposito (R-NY-4)· Later · Aug 23, 2024
- Rep. Andrew R. Garbarino (R-NY-2)· Later · Sep 3, 2024
- Rep. Josh Harder (D-CA-9)· Later · Sep 10, 2024
- Rep. Jerrold Nadler (D-NY-12)· Later · Oct 25, 2024
- Rep. Susie Lee (D-NV-3)· Later · Nov 20, 2024
- Rep. Claudia Tenney (R-NY-24)· Later · Dec 5, 2024
- Rep. Ken Calvert (R-CA-41)· Later · Dec 9, 2024
- Rep. Lloyd Doggett (D-TX-37)· Later · Dec 16, 2024
- Rep. Nicole Malliotakis (R-NY-11)· Later · Dec 17, 2024
- Policy area
- Health
- Subjects
- Administrative law and regulatory procedures
- Animal protection and human-animal relationships
- Congressional oversight
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Food and Drug Administration (FDA)
- Government information and archives
- Internet, web applications, social media
1 more
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · Feb 6, 2024 – Feb 9, 2024
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Feb 29, 2024 · Hearing
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
FDA Modernization Act 3.0
Display title, Short title · Introduced in House
To amend the Federal Food, Drug, and Cosmetic Act to establish a process for the qualification of nonclinical testing methods to reduce and replace the use of animals in nonclinical research, improve the predictivity of nonclinical testing methods, and reduce development time for a biological product or other drug, and for other purposes.
Official title · Introduced in House